ArticleScientific reports2025
Exploring the mechanism of PFTrDA on human hepatic metabolic diseases based on network toxicology and molecular docking.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
One of the most common and extensively disseminated endocrine disrupting chemicals (EDCs) is perfluorotridecanoic acid (PFTrDA), which is used extensively in food packaging and has been linked to the development of metabolic disorders. Human health and food safety are intimately intertwined. Thus, as exemplary hepatic metabolic diseases, we selected liver cancer and nonalcoholic fatty liver disease (NAFLD). By employing advanced network toxicology and molecular docking techniques, we have discovered potential molecular pathways underlying these two diseases. We pinpointed the potential targets associated with the disease by leveraging databases including PubChem, ADEMTlab3.0, Swiss Target Prediction, OMIM, and GeneCards. To identify the primary targets that were most closely connected to these metabolic disorders, we also used Cytoscape software and STRING analysis. Furthermore, the David database's Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were used to perform enrichment analysis of these key targets. Lastly, we used AutoDock Vina molecular docking to confirm PFTrDA's binding affinity to these target proteins. Our results imply that PFTrDA may regulate fatty acid metabolism and impact signal transduction pathways, which may lead to the onset of metabolic disorders. It's interesting that we also discovered links between liver cancer and NAFLD. In summary, this study offers a theoretical foundation for comprehending the molecular mechanisms behind PFTrDA toxicity and lays forth a basic theoretical framework for the creation of therapeutic and preventative approaches for hepatic metabolic disorders linked to PFTrDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.